Mr. Longman is recognized as an expert in biopharmaceutical strategy and reimbursement and often speaks at key industry events organized by important trade organizations, investment banks, venture capital firms, and leading biopharma companies. His most recent focus has been on new value-based approaches to paying for drugs and diagnostics, harnessing tools and systems for objective, transparent analysis of drug value and economic impact. He is developing these initiatives in collaboration with major provider, payer, pharmaceutical and diagnostic companies, and patient organizations.
Mr. Longman has been involved with the health-care industry for more than 30 years. At his first venture, Windhover Information, he and his team created a number of industry-standard analytical sources, including must-read strategy publications such as IN VIVO and Start-Up, the strategic transactions database and a major conference business for senior executives. The business was acquired by Elsevier where for two years Longman ran the company’s pharmaceutical business information group.
Mr. Longman lectures regularly at several leading universities and co-directed the Wharton-Windhover pharmaceutical program at The Wharton School. Mr. Longman completed his BA at Cornell University and MA at the University of North Carolina at Chapel Hill, then taught for three years at the European division of the University of Maryland.